Neurocrine review highlights key differences between tardive dyskinesia drugs

Johnson & Johnson gets FDA nod for new depression treatment

This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials

MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain

Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion

The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience

Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast

ALS patients experience neuroinflammation and rapid neurodegeneration

BioAge appoints former GSK CEO Jean-Pierre Garnier as Chair of its Board of Directors

New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development

CCRAS to organize national consultative meet on ‘Research Priority Settings in Traditional Medicine’ in collaboration with WHO

The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression

Ayush gets big boost in the North East

India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid

Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders

In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers